Symbols / IMNN Stock $2.02 +0.50% Imunon, Inc.

Healthcare • Biotechnology • United States • NCM
IMNN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Stacy R. Lindborg Ph.D.
Exch · Country NCM · United States
Market Cap 8.49M
Enterprise Value 6.28M
Income -14.64M
Sales —
FCF (ttm) —
Book/sh 0.67
Cash/sh 0.95
Employees 20
Insider 10d —
IPO Mar 01, 1999
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.93
PEG 5.03
P/S —
P/B 3.02
P/C —
EV/EBITDA -0.43
EV/Sales —
Quick Ratio 1.15
Current Ratio 1.59
Debt/Eq 27.14
LT Debt/Eq —
EPS (ttm) -4.52
EPS next Y -2.18
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-12
Earnings (prior) 2026-05-12
ROA -124.43%
ROE -7.68%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 4.20M
Shs Float 4.50M
Insider Own 1.47%
Instit Own 11.99%
Short Float 1.38%
Short Ratio 1.17
Short Interest 57.62K
52W High 22.43
vs 52W High -91.00%
52W Low 1.96
vs 52W Low 3.27%
Beta 1.93
Impl. Vol. —
Rel Volume 0.34
Avg Volume 99.40K
Volume 33.38K
Target (mean) $17.00
Tgt Median $13.00
Tgt Low $10.00
Tgt High $25.00
# Analysts 5
Recom Strong_buy
Prev Close $2.01
Price $2.02
Change 0.50%
About

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$17.00
Mean price target
2. Current target
$2.02
Latest analyst target
3. DCF / Fair value
$17.00
Proxy: analyst mean price target (no FCF/EPS data available).
Ratings
Current target
$2.02
Low
$10.00
High
$25.00
Mean
$17.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-17 init Maxim Group — → Buy $10
2025-05-19 down D. Boral Capital Buy → Hold —
2025-05-13 main D. Boral Capital Buy → Buy $17
2025-05-07 main D. Boral Capital Buy → Buy $29
2025-03-26 reit HC Wainwright & Co. Buy → Buy $14
2025-03-24 main D. Boral Capital Buy → Buy $29
2025-02-27 main D. Boral Capital Buy → Buy $29
2025-02-19 main D. Boral Capital Buy → Buy $29
2025-01-24 main D. Boral Capital Buy → Buy $29
2024-12-19 reit HC Wainwright & Co. Buy → Buy $12
2024-12-19 main D. Boral Capital Buy → Buy $29
2024-12-11 reit HC Wainwright & Co. Buy → Buy $12
2024-12-10 main D. Boral Capital Buy → Buy $29
2024-11-25 main D. Boral Capital Buy → Buy $29
2024-11-11 main HC Wainwright & Co. Buy → Buy $12
2024-11-07 main EF Hutton Buy → Buy $29
2024-10-31 main EF Hutton Buy → Buy $29
2024-09-23 init EF Hutton — → Buy $29
2024-08-15 reit HC Wainwright & Co. Buy → Buy $14
2024-08-05 main HC Wainwright & Co. Buy → Buy $14
News
RSS: Latest IMNN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-22 PELLIZZARI CHRISTINE A Director — 5,557 $2.20 $12,225
2026-05-22 TARDUGNO MICHAEL H Officer and Director — 3,484 $2.20 $7,665
2026-05-22 DENTZER JAMES E Director — 11,148 $2.20 $24,526
2026-05-22 BRAUN DONALD P Director — 5,011 $2.20 $11,024
2026-05-22 LINDBORG STACY R Chief Executive Officer — 1,491 $2.20 $3,280
2026-05-22 FRITZ FREDERICK J Director — 10,330 $2.20 $22,726
2025-09-05 LINDBORG STACY R Chief Executive Officer — 1,667 — —
2025-08-04 PELLIZZARI CHRISTINE A Director — 2,248 $9.20 $20,682
2025-08-04 DENTZER JAMES E Director — 3,318 $9.20 $30,526
2025-08-04 BRAUN DONALD P Director — 2,040 $9.20 $18,768
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
-100.00%
0.50
Operating Revenue
0.00
0.00
0.00
-100.00%
0.50
Operating Expense
14.65
-23.42%
19.13
-9.02%
21.03
-17.27%
25.42
Research And Development
7.78
-33.15%
11.64
+3.12%
11.29
-3.80%
11.73
Selling General And Administration
6.87
-8.31%
7.49
-23.09%
9.74
-28.82%
13.69
General And Administrative Expense
6.87
-8.31%
7.49
-23.09%
9.74
-28.82%
13.69
Other Gand A
6.87
-8.31%
7.49
-23.09%
9.74
-28.82%
13.69
Total Expenses
14.65
-23.42%
19.13
-9.02%
21.03
-17.27%
25.42
Operating Income
-14.65
+23.42%
-19.13
+9.02%
-21.03
+15.61%
-24.92
Total Operating Income As Reported
-14.65
+23.42%
-19.13
+9.02%
-21.03
+15.61%
-24.92
EBITDA
-13.95
+24.23%
-18.41
+7.36%
-19.88
+37.30%
-31.71
Normalized EBITDA
-14.11
+25.46%
-18.93
+5.28%
-19.98
+15.64%
-23.69
Reconciled Depreciation
0.70
-2.68%
0.72
-0.26%
0.72
-1.59%
0.73
EBIT
-14.65
+23.42%
-19.13
+7.12%
-20.60
+36.50%
-32.44
Total Unusual Items
0.16
-69.61%
0.51
+399.02%
0.10
+101.28%
-8.02
Total Unusual Items Excluding Goodwill
0.16
-69.61%
0.51
+399.02%
0.10
+101.28%
-8.02
Special Income Charges
—
0.00
+100.00%
-0.33
+95.87%
-7.97
Other Special Charges
—
—
0.33
—
Impairment Of Capital Assets
—
—
0.00
-100.00%
13.37
Restructuring And Mergern Acquisition
—
—
0.00
+100.00%
-5.40
Net Income
-14.50
+22.15%
-18.62
+4.58%
-19.51
+45.64%
-35.90
Pretax Income
-14.50
+22.15%
-18.62
+10.46%
-20.80
+44.49%
-37.47
Net Non Operating Interest Income Expense
—
0.45
-14.85%
0.53
+111.68%
-4.53
Interest Expense Non Operating
—
0.00
-100.00%
0.20
-96.08%
5.03
Net Interest Income
—
0.45
-14.85%
0.53
+111.68%
-4.53
Interest Expense
—
0.00
-100.00%
0.20
-96.08%
5.03
Interest Income Non Operating
—
0.45
-37.97%
0.73
+44.42%
0.50
Interest Income
—
0.45
-37.97%
0.73
+44.42%
0.50
Other Income Expense
0.16
-69.61%
0.51
+274.41%
-0.29
+96.34%
-8.02
Other Non Operating Income Expenses
—
—
-0.40
-22105.50%
0.00
Gain On Sale Of Security
0.16
-69.61%
0.51
+18.62%
0.43
+977.25%
-0.05
Tax Provision
—
0.00
+100.00%
-1.28
+18.29%
-1.57
Tax Rate For Calcs
0.00
0.00
-100.00%
0.00
+48.78%
0.00
Tax Effect Of Unusual Items
0.00
0.00
-100.00%
0.01
+101.90%
-0.33
Net Income From Continuing Operation Net Minority Interest
-14.50
+22.15%
-18.62
+4.58%
-19.51
+45.64%
-35.90
Net Income From Continuing And Discontinued Operation
-14.50
+22.15%
-18.62
+4.58%
-19.51
+45.64%
-35.90
Net Income Continuous Operations
-14.50
+22.15%
-18.62
+4.58%
-19.51
+45.64%
-35.90
Normalized Income
-14.65
+23.42%
-19.13
+2.44%
-19.61
+30.47%
-28.21
Net Income Common Stockholders
-14.50
+22.15%
-18.62
+4.58%
-19.51
+45.64%
-35.90
Diluted EPS
-6.83
+67.68%
-21.13
+25.00%
-28.17
+57.06%
-65.61
Basic EPS
-6.83
+67.68%
-21.13
+25.00%
-28.17
+57.06%
-65.61
Basic Average Shares
2.12
+140.67%
0.88
+27.23%
0.69
+26.63%
0.55
Diluted Average Shares
2.12
+140.67%
0.88
+27.23%
0.69
+26.63%
0.55
Diluted NI Availto Com Stockholders
-14.50
+22.15%
-18.62
+4.58%
-19.51
+45.64%
-35.90
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
12.29
+26.46%
9.72
-55.67%
21.92
-50.16%
43.98
Current Assets
10.72
+33.90%
8.01
-56.09%
18.24
-50.41%
36.78
Cash Cash Equivalents And Short Term Investments
8.78
+49.52%
5.87
-62.58%
15.70
-52.07%
32.75
Cash And Cash Equivalents
8.78
+49.52%
5.87
+0.59%
5.84
-49.20%
11.49
Other Short Term Investments
—
0.00
-100.00%
9.86
-53.62%
21.25
Receivables
—
—
0.00
-100.00%
0.13
Accrued Interest Receivable
—
—
0.00
-100.00%
0.13
Prepaid Assets
—
—
—
—
Restricted Cash
—
—
0.00
-100.00%
1.50
Other Current Assets
1.94
-9.06%
2.14
-16.06%
2.55
+5.89%
2.40
Total Non Current Assets
1.56
-8.43%
1.71
-53.54%
3.68
-48.90%
7.20
Net PPE
1.51
-8.69%
1.66
-29.34%
2.35
+233.29%
0.70
Accumulated Depreciation
-1.28
-6.66%
-1.20
+43.10%
-2.10
+20.48%
-2.64
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
1.11
-1.15%
1.12
-50.22%
2.25
-20.28%
2.82
Other Properties
0.98
-11.88%
1.12
-29.96%
1.60
+923.30%
0.16
Leases
0.70
+13.11%
0.62
+1.97%
0.61
+62.66%
0.37
Goodwill And Other Intangible Assets
—
—
—
0.00
Goodwill
—
—
—
—
Non Current Deferred Assets
—
0.00
-100.00%
1.28
-18.29%
1.57
Non Current Deferred Taxes Assets
—
0.00
-100.00%
1.28
-18.29%
1.57
Non Current Prepaid Assets
—
—
—
—
Other Non Current Assets
0.05
+0.00%
0.05
+0.00%
0.05
-98.98%
4.92
Total Liabilities Net Minority Interest
5.23
-4.51%
5.47
-35.84%
8.53
-41.76%
14.65
Current Liabilities
4.62
-3.39%
4.79
-35.24%
7.39
-26.36%
10.04
Payables And Accrued Expenses
4.22
-2.68%
4.33
-37.24%
6.91
-17.61%
8.38
Payables
1.39
+7.14%
1.30
-63.02%
3.52
-1.99%
3.59
Accounts Payable
1.39
+7.14%
1.30
-63.02%
3.52
-1.99%
3.59
Other Payable
—
—
1.44
-34.33%
2.20
Current Accrued Expenses
2.82
-6.89%
3.03
-10.52%
3.39
-29.29%
4.79
Current Debt And Capital Lease Obligation
0.41
-10.17%
0.45
-6.81%
0.49
-70.68%
1.66
Current Debt
—
—
—
1.42
Other Current Borrowings
—
—
—
1.42
Current Capital Lease Obligation
0.41
-10.17%
0.45
-6.81%
0.49
+110.37%
0.23
Current Deferred Liabilities
—
—
—
0.00
Current Deferred Revenue
—
—
—
0.00
Total Non Current Liabilities Net Minority Interest
0.60
-12.30%
0.69
-39.71%
1.14
-75.29%
4.61
Long Term Debt And Capital Lease Obligation
0.60
-12.30%
0.69
-39.71%
1.14
-75.29%
4.61
Long Term Debt
—
—
—
4.61
Long Term Capital Lease Obligation
0.60
-12.30%
0.69
-39.71%
1.14
0.00
Non Current Deferred Liabilities
—
—
—
—
Non Current Deferred Revenue
—
—
—
—
Other Non Current Liabilities
—
—
—
—
Stockholders Equity
7.06
+66.39%
4.24
-68.30%
13.39
-54.35%
29.33
Common Stock Equity
7.06
+66.39%
4.24
-68.30%
13.39
-54.35%
29.33
Capital Stock
0.03
+253.75%
0.01
-89.72%
0.09
+26.41%
0.07
Common Stock
0.03
+253.75%
0.01
-89.72%
0.09
+26.41%
0.07
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
3.42
+207.60%
1.11
+54.27%
0.72
+26.41%
0.57
Ordinary Shares Number
3.42
+207.60%
1.11
+54.27%
0.72
+26.41%
0.57
Treasury Shares Number
0.00
+100.00%
0.00
+0.00%
0.00
+0.00%
0.00
Additional Paid In Capital
428.41
+4.21%
411.12
+2.40%
401.50
+0.88%
397.98
Retained Earnings
-421.30
-3.56%
-406.80
-4.80%
-388.18
-5.29%
-368.67
Gains Losses Not Affecting Retained Earnings
—
0.00
-100.00%
0.06
+129.47%
0.03
Treasury Stock
0.09
+0.00%
0.09
+0.00%
0.09
+0.00%
0.09
Other Equity Adjustments
—
—
0.06
+129.47%
0.03
Total Equity Gross Minority Interest
7.06
+66.39%
4.24
-68.30%
13.39
-54.35%
29.33
Total Capitalization
7.06
+66.39%
4.24
-68.30%
13.39
-60.55%
33.94
Working Capital
6.10
+89.27%
3.22
-70.30%
10.85
-59.43%
26.74
Invested Capital
7.06
+66.39%
4.24
-68.30%
13.39
-62.14%
35.36
Total Debt
1.01
-11.46%
1.14
-29.88%
1.62
-74.07%
6.27
Capital Lease Obligations
1.01
-11.46%
1.14
-29.88%
1.62
+604.10%
0.23
Net Tangible Assets
7.06
+66.39%
4.24
-68.30%
13.39
-54.35%
29.33
Tangible Book Value
7.06
+66.39%
4.24
-68.30%
13.39
-54.35%
29.33
Interest Payable
—
—
0.00
-100.00%
0.04
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-13.90
+26.30%
-18.85
+0.88%
-19.02
+17.64%
-23.10
Cash Flow From Continuing Operating Activities
-13.90
+26.30%
-18.85
+0.88%
-19.02
+17.64%
-23.10
Net Income From Continuing Operations
-14.50
+22.15%
-18.62
+4.58%
-19.51
+45.64%
-35.90
Depreciation Amortization Depletion
0.70
-2.68%
0.72
-0.26%
0.72
-1.59%
0.73
Depreciation
0.70
-2.68%
0.72
-0.26%
0.72
-1.59%
0.73
Depreciation And Amortization
0.70
-2.68%
0.72
-0.26%
0.72
-1.59%
0.73
Other Non Cash Items
0.10
—
0.06
+100.96%
-5.71
Stock Based Compensation
0.13
-73.31%
0.48
-37.12%
0.76
-71.60%
2.67
Asset Impairment Charge
—
0.00
-100.00%
0.38
-97.19%
13.37
Deferred Tax
0.00
-100.00%
1.28
+346.69%
0.29
+256.14%
-0.18
Deferred Income Tax
0.00
-100.00%
1.28
+346.69%
0.29
+256.14%
-0.18
Operating Gains Losses
—
-0.06
-117.05%
0.36
+954.49%
0.03
Gain Loss On Investment Securities
—
-0.06
-280.70%
0.03
-0.48%
0.03
Change In Working Capital
-0.33
+87.63%
-2.65
-28.17%
-2.07
-209.09%
1.89
Change In Receivables
—
0.00
-100.00%
0.07
+439.19%
-0.02
Change In Prepaid Assets
0.19
-52.67%
0.41
+388.70%
-0.14
-422.01%
0.04
Change In Payables And Accrued Expense
-0.52
+82.96%
-3.06
-53.41%
-1.99
-194.37%
2.11
Change In Accrued Expense
—
—
—
1.07
Change In Payable
—
—
—
1.04
Change In Account Payable
—
—
—
1.04
Change In Other Working Capital
—
—
—
-0.50
Change In Other Current Assets
—
—
0.00
+100.00%
-0.24
Investing Cash Flow
-0.28
-102.85%
9.83
-10.70%
11.01
+32.91%
8.28
Cash Flow From Continuing Investing Activities
-0.28
-102.85%
9.83
-10.70%
11.01
+32.91%
8.28
Net PPE Purchase And Sale
-0.28
-849.77%
-0.03
+93.46%
-0.45
-68.69%
-0.27
Purchase Of PPE
-0.28
-849.77%
-0.03
+93.46%
-0.45
-68.69%
-0.27
Capital Expenditure
-0.28
-849.77%
-0.03
+93.46%
-0.45
-68.69%
-0.27
Net Investment Purchase And Sale
0.00
-100.00%
9.86
-13.96%
11.46
+34.04%
8.55
Purchase Of Investment
0.00
+100.00%
-0.06
+99.58%
-13.54
+71.92%
-48.23
Sale Of Investment
0.00
-100.00%
9.92
-60.34%
25.00
-55.97%
56.77
Financing Cash Flow
17.09
+88.57%
9.06
+349.01%
-3.64
-154.12%
6.72
Cash Flow From Continuing Financing Activities
17.09
+88.57%
9.06
+349.01%
-3.64
-154.12%
6.72
Net Issuance Payments Of Debt
—
0.00
+100.00%
-6.42
0.00
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
—
0.00
+100.00%
-6.42
0.00
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
—
0.00
+100.00%
-6.42
0.00
Net Long Term Debt Issuance
—
0.00
+100.00%
-6.42
0.00
Net Common Stock Issuance
13.63
+50.41%
9.06
+225.75%
2.78
-58.63%
6.72
Common Stock Dividend Paid
-0.01
0.00
—
—
Cash Dividends Paid
-0.01
0.00
—
—
Repurchase Of Capital Stock
—
—
0.00
+100.00%
-28.50
Proceeds From Stock Option Exercised
3.47
0.00
—
0.00
Changes In Cash
2.91
+8403.53%
0.03
+100.29%
-11.65
-44.00%
-8.09
Beginning Cash Position
5.87
+0.59%
5.84
-66.62%
17.49
-31.63%
25.59
End Cash Position
8.78
+49.52%
5.87
+0.59%
5.84
-66.62%
17.49
Free Cash Flow
-14.18
+24.93%
-18.88
+3.03%
-19.47
+16.65%
-23.36
Interest Paid Supplemental Data
—
0.00
-100.00%
0.18
-96.30%
4.85
Income Tax Paid Supplemental Data
—
—
0.00
+25.00%
0.00
Common Stock Issuance
13.63
+50.41%
9.06
+225.75%
2.78
-58.63%
6.72
Issuance Of Capital Stock
13.63
+50.41%
9.06
+225.75%
2.78
-92.10%
35.22
Net Preferred Stock Issuance
—
—
0.00
0.00
Preferred Stock Issuance
—
—
0.00
-100.00%
28.50
Preferred Stock Payments
—
—
0.00
+100.00%
-28.50
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category